Virginia pharmacist Heather Greene receives C.A.R.E. Pharmacy Award
WOODCLIFF LAKE, N.J. Virginia pharmacist Heather Greene has won the C.A.R.E. Pharmacy Award from Eisai Corp. and the Alzheimer’s Association, Eisai and the association announced Thursday.
Greene, a geriatric consultant with the Riverside Health System at the Richmond Program for All-inclusive Care for the Elderly facility, received the award in recognition of her work with patients with Alzheimer’s disease. The award will include a $1,500 donation to the Greater Richmond Alzheimer’s Association Chapter, as well as the Massachusetts/New Hampshire and Illinois chapters because of the large number of nominations submitted from them.
“Alzheimer’s is a devastating disease for individuals as well as for their caregivers and family members,” Eisai president U.S. pharmaceuticals Cynthia Schwalm said in a statement. “Eisai recognizes the integral role pharmacists play in each patient’s treatment and care, through ongoing monitoring, counseling and support. We are proud to honor this year’s C.A.R.E. award recipient for her invaluable contributions to enhance the quality of care for people affected by Alzheimer’s disease.”
Cardinal Health Foundation, The Ohio State University College of Pharmacy join forces to prevent prescription medication abuse
DUBLIN, Ohio The Cardinal Health Foundation has awarded The Ohio State University College of Pharmacy a $100,000 grant to create education and outreach programs that empower pharmacists, colleges and universities to fight prescription medication abuse and misuse in their communities.
With help from the financial grant, The Ohio State University College of Pharmacy will develop educational materials to help pharmacists and pharmacy students educate their communities about the dangers of prescription medication abuse and misuse; how to safely store and dispose of prescription medications; how to identify signs and symptoms that someone they love may be abusing or misusing medications; and action steps they can take to prevent this issue in their homes and communities. According to a 2007 survey by the Ohio Department of Health, more than 25% of all Ohio high school students have reported using a prescription medication without a doctor’s prescription.
Shelley Bird, EVP Cardinal Health and chairperson of the Cardinal Health Foundation, said “We know that in most communities, patients look to their neighborhood pharmacist as the trusted healthcare resource they visit most. The goal of this funding is to develop tools and resources that pharmacists and pharmacy students can use to improve the overall health of their communities by educating patients and peers about how to detect and prevent the abuse and misuse of prescription medications.”
After an initial pilot rollout among Ohio pharmacies, colleges and universities, Cardinal Health and The Ohio State University College of Pharmacy plan to make these educational materials available for use nationwide.
“When used as intended, prescription and over-the-counter medications are safe and can improve and save lives. However, when they are not taken as intended, these medications can lead to addictions, health problems and even death,” said Ken Hale, assistant dean for professional and external affairs at The Ohio Sate University. “With more Americans abusing prescription drugs than cocaine, heroin, hallucinogens and inhalants combined, it’s clear that more needs to be done to combat this growing societal issue. With support from the Cardinal Health Foundation, the programming that we are developing will help more Americans understand prescription medication abuse and how to prevent it.”
Shire receives market exclusivity for ADHD drug
DUBLIN, Ireland A new drug for treating attention-deficit hyperactivity disorder properly received its five-year market exclusivity from the Food and Drug Administration, the drug’s manufacturer announced.
British drug maker Shire said the FDA confirmed the new chemical entity exclusivity given to Vyvanse (lisdexamfetamine dimesylate). The drug’s exclusivity period will last until February 2012, and its patents will remain in effect until June 2023.
Generic drug maker Actavis had sued the FDA in the District Court of the District of Columbia challenging the agency’s decision to grant Vyvanse status as a new chemical entity following its refusal to file Actavis’ approval application for a generic version of the drug. The court case was stayed pending the outcome of the FDA’s review.